Abstract Transfusion dependency and iron overload are common among patients with myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with leukemic progression and shorter survival. Guidelines recommend iron chelation therapy to manage iron overload, however little is known about the chelation patterns in daily clinical practice. The objective of this multicenter, retrospective, cross-sectional, observational study was to evaluate iron status and its management in transfusion-dependent MDS patients. A total of 193 patient records from 29 centers were eligible for inclusion. Median patient age was 76, and median age at diagnosis of MDS was 74. Patients had received an average of 13.4±7.6 RBC units in the past 4 months; 44% had received more than 50 units since their MDS diagnosis. Medium serum ferritin was 1,550 μg/L. Ninety patients (46.6%) received iron chelation therapy with either deferoxamine (41%), deferasirox (36%), and deferoxamine followed by deferasirox (23%). There were no statistically significant differences between chelated and nonchelated patients in terms of International Prognostic Scoring System (IPSS), French-American-British (FAB), and/or World Health Organization (WHO) status, though chelated patients had received more RBC transfusions (p= 0.014). Iron chelation therapy may be underutilized in transfusion-dependent patients. Undertreatment can be reduced by complementing sound clinical judgment with the generally accepted guidelines of a serum ferritin level >1,000 μg/L and/or two or more RBC transfusions per month for the past year; considering patients on the basis of their IPSS, FAB, and/or WHO status; and individually tailored treatment regimens. Prospective randomized trials are necessary to establish causally the efficacy of iron chelation therapy in MDS. 
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders characterized by cytopenias due to ineffective production of normal mature blood cells, with course of disease and prognosis dependent on subtype [1] [2] [3] [4] [5] [6] [7] [8] [9] . Up to 30% of patients progress to acute myelogenous leukemia (AML); while up to 65% of nonprogressing MDS patients will develop progressive cytopenia(s) [5] . As cancer registries seldom include MDS and epidemiological studies have varied in methodological quality, reliable estimates are scant [5] . The Düsseldorf (Germany) registry reported an incidence rate of 4.9 per 100,000 population for the period 1991-2001 (5.5 for men vs. 4.4 for women) [10] . Using 2002-2006 data, the US National Cancer Institute (NCI) estimated the annual ageadjusted incidence rate at 4.0 per 100,000 population (5.4 for men vs. 3.1 for women) or 14,324 new cases per year [11] . Though MDS may occur at any age, it is mainly a disease of old age, with men at greater risk. The Düsseldorf age-adjusted incidence rates per 100,000 population were 24.5 in the 70-80 age group (38.8 for men vs. 17.8 for women) and 31.3 in the 80-90 age group (53.6 for men vs. 23 .64 for women) [11] . In the NCI analysis, age-adjusted incidence rates were 24.8 per 100,000 in the 70-79 age group (33.9 for men vs. 17.9 for women) and 43.9 in the age 80 and older group (65.6 for men vs. 32.2 for women).
From 80% to well over 90% of MDS patients develop anemia, with over half presenting with hemoglobin levels below 10 g/dL [12] [13] [14] . Almost all MDS patients are likely to require red blood cell (RBC) transfusions at some point, and for 40% of patients this will be the sole therapeutic option to manage their anemia, prevent anemia-related comorbidity and decline in physical performance, and enhance quality of life [1] . Despite these potential benefits, transfusion dependence in MDS patients is associated with increased risk of disease progression [4, 13, 15, 16] and shorter survival [4, 13, 15, 17] . The increased mortality risk is a function of disease severity, and the increased risk of leukemic progression, severity of anemia, and iron overload and the associated risk for end organ damage.
As one unit of blood contains between 100 and 250 mg of iron [3, 18] transfusion-dependent patients with MDS invariably develop iron overload at a rate of approximately 0.5 mg/kg of body weight per day [19] and typically after ten to 20 transfusions [2, 20] . The circulating nontransferrinbound iron produces hydroxyl and oxygen radicals that cause lipid peroxidation and damage to cell membranes, protein, and DNA [2, 21] , especially in target organs such as heart, liver, and endocrine glands [1, 22] . Iron overload is associated with reduced survival: adjusting for transfusion burden, hazard rates increase by 30% for every 500 μg/L increase in serum ferritin above the threshold of 1,000 μg/L [4] .
Recognizing that blood transfusions are therapeutically beneficial to manage anemia in MDS patients but that transfusional iron overload must be monitored and managed, several guidelines recommend iron chelation therapy [13, 14, 18, [23] [24] [25] [26] , especially for patients with a good prognosis and a high transfusion requirement [26, 27] . As these guidelines were published between 2002 [14] and 2010 [26] , there are some historical differences; however, there is growing consensus that iron chelation therapy should be initiated when a patient's serum ferritin reaches 1,000 μg/L, and/or after the patient has received two units of RBCs a month for at least 1 year [27] . A recent review argued that the benefits of iron chelation therapy go beyond the reduction of cardiac and other end organ damage and also include reduced infection risk, improved survival after allogeneic hematopoietic stem cell transplantation, and delay of leukemic progression [28] . As a caveat, though, the evidence to date in support of iron chelation in MDS is from observational studies, not from randomized controlled trials.
Two iron chelating agents are approved worldwide, parenteral deferoxamine (Desferal®, Novartis) and oral deferasirox (Exjade®, Novartis). A third oral agent, deferiprone (Ferriprox®, Apopharma) is approved in some Asian and European countries, but not in the USA and Canada due to safety concerns [19, [29] [30] [31] . Deferoxamine is administered through slow continuous infusion over 8 to 12 h over 5 to 7 days/week, and the burden of this regimen impacts patient adherence. Deferiprone dosing is thrice daily p.o., whereas deferasirox is taken p.o. once daily.
The introduction of the orally available iron chelator deferasirox has renewed the interest in the management of transfusion-related hemochromatosis in MDS. However, little is known about chelation patterns according to transfusion practice and ferritin levels in daily clinical practice. The objective of the multicenter retrospective observational study reported here was to evaluate iron status and its management in transfusion-dependent MDS patients.
Methods

Study design
This was a multicenter, retrospective, observational, noninterventional study with a cross-sectional descriptive correlational design. Being observational, there were no mandatory treatments, tests, and other procedures. Any treatment decisions were per the treating physician's best clinical judgment. All data recorded were as available in routine clinical practice. The study was conducted in 29 hematology centers throughout Belgium: ten university centers and 19 regional medical centers.
The study was approved by the ethical committee of each participating center. The study was conducted in accordance with the Helsinki Declaration of the World Medical Association as most recently amended.
Patients
Both male and female adults (age≥18) were eligible, provided they were diagnosed with one of the French-American-British (FAB) and/or World Health Organization (WHO) MDS subtypes and were transfusion dependent. Transfusion dependence was defined as having received at least one RBC transfusion every 8 weeks over a period of 4 months prior to inclusion in the study [15] . All patients (or their legal guardian) provided written informed consent.
Variables
Data as available from the medical record and used in the statistical analysis included: patient demographics (age and gender); current medical status and comorbidities (diabetes, signs of heart failure, other cardiovascular disease, abnormal liver tests, and other severe comorbidities with potential impact on survival); history of MDS (date of diagnosis, FAB and/or WHO classification at diagnosis, and prognostic classification (International Prognostic Scoring System (IPSS)) at diagnosis); cytogenetic risk group at diagnosis (conventional karyotype or fluorescence in situ hybridization [12] ); previous MDS treatments (growth factors, immunomodulatory agents, chemotherapy, and allogeneic transplantation); most recent red blood cell hematology (RBC, hemoglobin, and hematocrit) and serum ferritin levels; blood transfusion history (number of RBC units since diagnosis and number of RBC units in the past 4 months); iron chelation therapy (if any, agent and route of administration); and, if applicable, reason for nonchelation. Iron overload was defined as a serum ferritin level ≥1,000 μg/L.
Procedures
Each center identified potential subjects from patient files and current active case load and compared them to the eligibility criteria. To optimize case-finding, centers also queried their associated blood transfusion centers to identify transfusion-dependent MDS patients. The chart reviews were performed between 11 September and 12 November 2008.
Statistical analysis
Descriptive statistics for continuous variables included measures of central tendency and dispersion; for discrete variables, counts, percentages, and proportions were calculated. Tests of significance included Student's t test for independent samples and analysis of variance for respectively 2 and ≥3 subgroup comparisons on continuous variables; and χ 2 -based contingency analysis with, as applicable, Yates' correction for 2×2 tables. Bonferonni class corrections were used to monitor for multiplicity. The statistical significance level was set at α= 0.05. Statistical analysis was performed using SPSS® v.15 (IBM, Chicago, IL).
Results
Patient characteristics at baseline
A total of 193 patient records were eligible for inclusion in this observational study and constituted the evaluable sample. The 29 participating centers contributed between and one and 20 patients for a median of five patients per center. Tables 1 and 2 summarize patient characteristics and clinical status at the time of inclusion in the study, including comorbidities, MDS subtypes (FAB and WHO), and cytogenetics (IPSS risk score). The median age was 76 years (range, 44-103); the median age at which the MDS diagnosis was made was 74 years (range, 39-95); and the median time between diagnosis and start of study was 2 years. For 25% of patients, it had been 4 or more years since MDS was diagnosed.
Some centers used the FAB, some the WHO, and some both classification methods. The most common types of MDS were refractory anemia without or with ringed sideroblasts (64.7% per FAB and 38.9% per WHO). Of the 149 patients with known IPSS score at diagnosis, 87.9% were in the low or intermediate one category. Similarly, 85 (81.7%) of the 104 patients tested cytogenetically fell in the favorable risk category. Most patients (74.6%) had at least one comorbidity, with cardiovascular disease (51.3%, including signs of heart failure) being the most common.
Anemia, transfusion, and iron status RBC count and hemoglobin and hematocrit levels confirmed that patients were severely anemic. On average, they had received 13.4±7.6 RBC units in the past 4 months; 44.0% had received more than 50 units since being diagnosed with MDS. Medium serum ferritin was 1,550 μg/L; the 75th percentile was 2,502 μg/L (Tables 1 and 2 ).
Iron chelation therapy
Ninety patients (46.6%) received iron chelation therapy (Table 3 ). Treatment flow charts by IPSS, FAB, and WHO classification are presented in Figs. 1, 2 , and 3. Of the 90 chelated patients, 37 (41.1%) received deferoxamine, mainly intravenously (33, 84.6%); 32 (35.6%) were treated with deferasirox; and for 21 (23.3%), deferasirox was given after prior deferoxamine therapy (in accordance with the current Belgian reimbursement guidelines, which specify that deferasirox may be initiated if at least 6 months of prior deferoxamine therapy did not lead to controlled serum ferritin levels). The time between MDS diagnosis and initiation of chelation therapy ranged from 1 month to 32 years (M ± SD=3.4±4.0 years; Mdn=2); 25% of patients had been diagnosed six or more years prior to start of chelation therapy. The median duration of treatment with Reasons for nonchelation were provided for 98 of the 103 nonchelated patients (183 reasons or an average of two per patient) and for 53 of the 56 nonchelated patients above the 1,000 μg/L serum ferritin threshold (110 reasons or average of two per patient) ( Table 4 ).The frequencies of reasons cited were not statistically different between the two groups.
Discussion
Chelation therapy is recommended for MDS patients with iron overload secondary to blood transfusion, especially in patients with serum ferritin ≥1,000 μg/L and/or at least two RBC transfusions a month over the past year [2, 13, 14, 23, 24, 26, 27] . Chelation may significantly reduce total body iron load and decrease the production of hydroxyl and oxygen radicals, thus lessening cellular and target organ damage and eventually enhancing survival in transfusion-dependent MDS patients [1, 2, 21, 22] . Note, however, that the evidence for the use of chelation therapy in patients with MDS is based, not on randomized controlled trials, but on observational studies; including two recent ones which continue to provide evidence of an beneficial association between chelation therapy and iron status [32, 33] .
In this observational study of mainly severely anemic patients, the crude iron chelation treatment rate across all patients, regardless of serum ferritin levels, was 46.6% (90 out of 193 patients). This was higher than the 37.7% recently noted in a Spanish study [34] , however these percentages are not exactly comparable. In the Spanish study, only patients with Low or Intermediate-1 MDS and with serum ferritin levels ≥1,000 μg/L were considered for chelation, which moreover was by parenteral deferoxamine as deferasirox was not yet available in Spain. Of the 125 patients in our sample with known recent serum ferritin levels ≥,000 μg/L, 69 or 55.2% were chelated-higher than in the Spanish study yet still leaving nontreatment rates of 44.8% and 62.3%, respectively, in the Belgian and Spanish studies.
Patients with IPSS scores in the Low and Intermediate 1 (Int-1) categories; patients with FAB classification of refractory anemia without (RA) and with ringed sideroblasts (RARS); and/or patients with WHO classification of RA, RARS or 5q-syndrome (5q-), are considered good candidates for iron chelation therapy. Referring to Figs. 1, 2, and 3, of particular interest is the branch of 57 nonchelated patients with serum ferritin levels exceeding the 1,000 μg/L threshold. Using the IPSS criteria, an additional 41 out of 193 (21.2%) patients may have benefited from chelation therapy; also, a 42 (21.8%) when classifying according to the FAB system; and an additional 29 (15.0%) when applying the WHO classification. Arguably, if physicians had applied these criteria, between 119 (61.7%) and 132 (68.4%) of the total patient population would have received iron chelation.
While endorsing the importance of transfusion dependency (two RBC units/month for at least a year; serum ferritin >1,000 μg/L; Low or Int-1 IPSS; and/or WHO RA, RARS, and 5q-), the Consensus Statement by the MDS Foundation's Working Group on Transfusional Iron Overload identifies additional factors for evaluating candidates for chelation therapy: patients with a projected life expectancy of at least 1 year, patients without prognosislimiting comorbidities, allograft candidates, and patients with a need to preserve target organ function [13] . Because its serum levels are affected by inflammation and liver disease, ferritin has been argued to be an inadequate indicator of body iron content, should not be used for determining the need for iron chelation therapy, and should at best be used for monitoring such therapy [26] . Instead, iron chelation therapy is recommended in all patients with Int-1 IPSS risk disease who receive regular red-cell transfusion therapy after patients have received 20 packed RBC units (i.e., 4 g of iron). Furthermore, iron chelation therapy should be considered for transfusion-dependent patients with Int-2 and high IPSS risk disease when they are responding to therapies able to modify their life expectancy or have a hematopoietic stem cell transplantation in their therapeutic program [26] . Furthermore, it has been argued that advanced age or severe comorbidities should not preclude iron chelation therapy [1] , though careful evaluation of patients' frailty and consideration of life expectancy are recommended [2] . Other relevant decision factors include patients with elevated serum ferritin levels at the time of MDS diagnosis, in particular those with acquired sideroblastic anemia because of the risk of hematochromatosis [5] , and patients on more liberal transfusion strategies where the target hemoglobin is higher than the 8-10 g/dL typically maintained in MDS patients [1] . In fact, individually tailoring deferasirox dose to achieve therapeutic targets, with initial dosing based on transfusion requirements and titration per follow-up monitoring data, is recommended [33] . Despite effectiveness data from observational studies, consensus statements, and guidelines, the absence of randomized controlled trials leaves some uncertainty about the efficacy of iron chelation therapy in patients with MDS. However, the position against chelation [35] [36] [37] is not warranted. It is now well established that adequately designed observational studies, though perhaps unable to provide causal evidence, provide accurate estimates of treatment effects [38, 39] These extant consensus and individual recommendations are helpful in reconciling some of the reasons physicians in our study cited for not chelating patients, including age, life expectancy, and comorbidities (Table 4) . Note in this regard that six patients with serum ferritin levels ≥1,000 μg/L were not chelated because their physician did not consider the threshold for chelation achieved, and seven because there had not been sufficient prior RBC transfusions. Lastly, there is evidence that, in some patients, effective long-term chelation (1-4 years) may stimulate haemopoiesis resulting in a return to transfusion independence [39] and decrease cardiac iron content [40] . This emphasizes the importance of applying generally accepted guidelines for iron chelation treatment while also considering individual patient factors beyond these guidelines to offer patients individualized treatment plans.
Nonadherence with iron chelation therapy is a known problem [41] [42] [43] , especially with deferoxamine due to the virtually daily, slow, continuous parenteral administration.
Physician influence should not be excluded: 16 of the 53 patients (30.2%) above the serum ferritin threshold of 1,000 μg/L were not chelated because their prescribing physician considered deferoxamine administration too cumbersome. Deferasirox's once daily oral dosing coupled with its tolerability [33, 44] offers a convenient alternative. There is evidence that deferasirox decreases the risk of iron overload in Low and Int-1 IPSS patients [24] , removes cardiac iron more effectively and prevents cardiac iron accumulation [45] , and lowers liver iron concentrations and labile plasma iron levels [34] . Clinician education about the importance of patient adherence should include this information, as well as such essentials as the potential negative effect of iron overload on heart, liver, and endocrine glands, and the associated increase in mortality risk.
The results of our study should be considered within the study's limitations and the directions for future research it provides. This was a retrospective observational study with a convenience sample and conducted in one European country; not a prospective population-based cohort study with random subject selection. A center-level bias of heightened vigilance about iron overload at participating centers cannot be excluded, certainly not in the 11 out of the 29 centers that have participated in trials of deferasirox. The study did not examine the effectiveness of iron chelation therapy, in part because of the availability of two agents with different routes of administration and the sequential use of both in 23% of patients. A comparative effectiveness study, let alone a randomized controlled efficacy trial, would be necessary for this. Importantly, such studies should assess the moderating impact of adherence on iron outcomes. Yet, unless the aim is to document the superiority of one agent over the other in Fig. 1 transfusion-dependent MDS patients with anemia, the relevance of such studies may be less evident. The equivalence of deferoxamine and deferasirox has been established in patients with β-thalassemia [45] and sickle cell disease [46] , and the pathogenesis of iron overload in these anemias is considered generalizable to other anemias requiring transfusion. The differential benefit of deferasirox is its convenience of once daily oral intake. Lastly, we considered only serum ferritin as marker of iron status, and future studies should include established markers like nontransferrin-bound iron, labile plasma iron, liver iron concentration, and magnetic resonance imaging of target organs. While the current guidelines provide general direction for identifying good candidates for iron chelation therapy, future research is needed to examine expanded patient profiles that may benefit from treatment.
Being observational, the present study does not address the need for randomized controlled trials.
Conclusions
Despite the known efficacy of chelation therapy for transfusion-induced iron overload, it is underutilized in the management of transfusion-dependent MDS patients in Belgium-even though this trend is unlikely to be limited to Belgium. Thus, this study provides further evidence of the need to optimize treatment strategies and algorithms for treating transfusional iron overload in patients with MDS. Undertreatment can be reduced by complementing sound clinical judgment with the generally accepted guidelines of Fig. 3 Treatment flow of all patients based on iron chelation therapy, serum ferritin values, and WHO classification. Green-shaded boxes in the nonchelated patient arm refer to categories of potential candidates for iron chelation therapy according to international recommendations. Abbreviations: RA refractory anemia, RAEB refractory anemia with excess of blasts, RAEB-II refractory anemia with excess of blasts II, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RSCMD refractory sideroblastic cytopenia with multilineage dysplasia, SF serum ferritin, WHO World Health Organization, 5q 5q syndrome 
